Streetbeat News

Equity Actions

VNRX

VolitionRx Limited (NYSE:VNRX) has priced an underwritten public offering of 13 million shares of common stock at $1.27 per share, expecting to raise $16.5 million in gross proceeds. The company plans to use the funds for research, product development, clinical studies, commercialization, working capital, and potential strategic acquisitions.

Portfolio Pulse from Happy Mohamed

June 01, 2023 | 1:30 pm

VNRX

VolitionRx Limited has announced the pricing of its $16.5 million public offering at $1.27 per share. The company plans to use the proceeds for general corporate purposes.

Portfolio Pulse from Benzinga Newsdesk

June 01, 2023 | 1:27 pm

T

T Stamp shares are trading lower after the company announced the pricing of a $2.9 million registered direct offering at $2.30 per share.

Portfolio Pulse from Benzinga Newsdesk

June 01, 2023 | 1:26 pm

LXRX

Lexicon Pharmaceuticals announced the pricing of a $125 million public offering and concurrent private placement, causing its shares to trade lower.

Portfolio Pulse from Benzinga Newsdesk

June 01, 2023 | 1:09 pm

LCID

Lucid Group announced a public offering of 173.54 million shares for $1.2 billion and a private placement of 265 million shares for $1.8 billion. The majority stockholder, Ayar Third Investment Company, will maintain 60.5% ownership. Lucid's stock price fell 13% following the announcement.

Portfolio Pulse from Adam Eckert

June 01, 2023 | 12:40 pm

LCID

Lucid Group announced a public offering of 173,544,948 shares of its common stock, with an affiliate of PIF investing for aggregate proceeds of ~$3.0 billion. This news has led to a decline in LCID's share price.

Portfolio Pulse from Benzinga Newsdesk

June 01, 2023 | 12:38 pm

IDAI

Trust Stamp announced the pricing of a $2.9 million registered direct offering at $2.30 per share.

Portfolio Pulse from Benzinga Newsdesk

June 01, 2023 | 12:32 pm

LXRX

Lexicon Pharmaceuticals announced the pricing of its $125M public offering of 23,924,705 shares at $2.60 per share and a concurrent private placement. The company plans to use the proceeds to fund the commercial launch of INPEFA and continued R&D of its drug candidates.

Portfolio Pulse from Happy Mohamed

June 01, 2023 | 12:18 pm

ANGN

Angion Biomedia Corp. has announced a 1-for-10 reverse stock split, which will reduce the number of outstanding shares and increase the stock price proportionally.

Portfolio Pulse from Benzinga Newsdesk

June 01, 2023 | 12:05 pm

QIPT

Quipt Home Medical has announced the termination of its At-The-Market (ATM) equity program.

Portfolio Pulse from Benzinga Newsdesk

June 01, 2023 | 11:32 am